𝔖 Bobbio Scriptorium
✦   LIBER   ✦

5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I — II study

✍ Scribed by Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, Raphael

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
189 KB
Volume
9
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

📜 SIMILAR VOLUMES

Phase I trial of trimetrexate in pediatr
Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study
✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

Phase I study of a 120-hour continuous i
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study
✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

Phase II study of 5-fluorouracil and fol
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study
✍ Giuseppe Colucci 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 3 views

n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our

A phase II study of homoharringtonine fo
A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: A pediatric oncology group study
✍ Bell, Beverly A. ;Chang, Myron N. ;Weinstein, Howard J. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract ## Background Homoharringtonine (HHT) is a plant alkaloid that is derived from a Chinese evergreen tree. Its mechanism of action is thought to be by inhibition of protein, DNA, and RNA synthesis by inhibition of chain initiation. The treatment of acute myelogenous leukemia (AML) in chi